Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Advances in bone marrow stem cell therapy for retinal dysfunction
Susanna S. Park
*
,
Elad Moisseiev
, Gerhard Bauer
, Johnathon D. Anderson
, Maria B. Grant
, Azhar Zam
, Robert J. Zawadzki
, John S. Werner
, Jan A. Nolta
*
Corresponding author for this work
Ophthalmology
University of California at Davis
Indiana University-Purdue University Indianapolis
University of Basel
Research output
:
Contribution to journal
›
Review article
›
peer-review
104
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Advances in bone marrow stem cell therapy for retinal dysfunction'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Age-related Macular Degeneration
16%
Autologous Therapy
16%
Blindness
16%
Bone Marrow Cells
100%
Bone Marrow Mononuclear Cells
16%
CD34+ Cells
33%
Cell Therapy
33%
Cellular Changes
16%
Damaged Tissue
16%
Diabetic Retinopathy
16%
Donor-recipient Matching
16%
Early Phase Clinical Trials
16%
Extracellular Vesicles
16%
Glaucoma
16%
High-resolution
16%
Intravitreal Administration
16%
Intravitreal Delivery
33%
Ischemic Retina
16%
Mesenchymal Stem Cells
33%
Mononuclear Cells
33%
Most Common Cause
16%
Multi-cell
16%
Paracrine
33%
Regenerative Effect
16%
Retina
66%
Retinal Dysfunction
100%
Retinal Imaging
16%
Retinal Regeneration
16%
Stem Cell Therapy
100%
Stem Cells
50%
Systemic Immunosuppression
16%
Therapeutic Potential
16%
Trophic Effects
33%
Vision Loss
16%
Medicine and Dentistry
Age Related Macular Degeneration
16%
Cell Therapy
33%
Clinical Trial
16%
Diabetic Retinopathy
16%
Glaucoma
16%
Hematopoietic Cell
100%
Immunosuppressive Treatment
16%
Intravitreal Administration
16%
Mesenchymal Stem Cell
33%
Mononuclear Cell
33%
Regeneration
16%
Retinal Imaging
16%
Stem Cell
66%
Stem Cell Therapy
100%
Visual Impairment
16%